• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Almac Group

    Adare Pharma Solutions

    Reed-Lane

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    PCI Pharma Services

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Evotec and Sartorius Partner with Curexsys

    Leverage IPSC platform for scalable manufacturing of Curexsys' exosome-based therapeutics.

    Related CONTENT
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • Alkermes, Merck Enter Clinical Trial and Supply Agreement
    • Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate
    • Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment
    • Moleculin Selects IQVIA Biotech to Advance COVID Treatment
    Contract Pharma Staff12.09.20
    Evotec SE and the life science company Sartorius have entered into a partnership with the recently established Curexsys GmbH, a Goettingen, Germany-based technology company specializing in the emerging field of therapeutic exosomes.

    Curexsys delivers a proprietary isolation technology for exosomes based on a traceless immune-affinity process. This process is different from commonly used antibody-based processes and enables the company to overcome a key hurdle in exosome preparation, i.e. remaining antibodies in the final preparation. Curexsys is founded by Herbert Stadler, a serial biotech entrepreneur, and Jens Gruber, a former group leader of Medical RNA Biology who is going to lead Curexsys as chief scientific officer.

    Producing Human Mesenchymal Stem Cells

    Under the terms of the agreement, Evotec and Curexsys will collaborate with the production of Human Mesenchymal Stem Cells ("MSCs"), which serve as a source for exosomes. These are small vesicles that are naturally released from a cell. They contain proteins, nucleic acids and metabolites, which carry information from secreting to receiving cells.
     
    Exosomes have immunomodulatory and anti-inflammatory effects, which makes them a promising novel approach for innovative regenerative therapies, as therapeutics in age-related conditions, but also for diagnostic purposes. Curexsys aims to develop targeted approaches for a variety of diseases, initially focusing on Sicca Syndrome, commonly known as "dry eye", an inflammatory condition affecting 14% to 17% of the adult population for whom there is currently no effective treatment available.

    The collaboration combines Evotec's industry-leading induced Pluripotent Stem Cell ("iPSC") platform with Curexsys' proprietary technology to selectively isolate exosomes. Sartorius will support Curexsys to set up a GMP-compliant and scalable manufacturing platform.

    Furthermore, Evotec and Sartorius have formed a consortium to jointly invest in Curexsys' €8.2 million ($9.9 million) seed financing round with Evotec acquiring an equity stake of approx. 37% in Curexsys and Sartorius of approx. 21%.

    Dr Cord Dohrmann, chief scientific officer of Evotec, commented, "Therapeutic exosomes hold significant promise for regenerative medicine and beyond. Steadily increasing evidence suggests that exosomes derived from stem cells can aid tissue repair and engineering vesicles could carry drugs to diseased tissues. These efforts have been held back by a dearth of standardized methods to isolate and study vesicles. Combining Evotec's industrial-grade iPSC and PanOmics platforms with Curexsys' proprietary exosome isolation technology and Sartorius' ability to translate these into a fully GMP-compliant process is a unique opportunity to build the leading exosome company in the industry."

    Dr René Faber, head of Sartorius' Bioprocess Solutions Division, added, "With our integrated portfolio of manufacturing solutions, Sartorius is the 'go-to' partner for developers of such new modalities when it comes to implementing GMP-compliant, flexible production processes. We are very much looking forward to contributing our proven and scalable technology platform to Curexsys process and help them achieve their next milestones faster."

    Dr Jens Gruber, chief scientific officer of Curexsys, remarked, "We are very happy that we were able to form such a consortium with industry leaders in their field. This unique constellation gives Curexsys an optimal starting position to advance our technologies for highly specific isolation of exosomes and to rapidly approach therapeutic applications."
     
    Related Searches
    • Drug Discovery
    • R&D
    Suggested For You
    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    Alkermes, Merck Enter Clinical Trial and Supply Agreement Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate
    Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment
    Moleculin Selects IQVIA Biotech to Advance COVID Treatment Moleculin Selects IQVIA Biotech to Advance COVID Treatment
    Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio
    Eloxx Pharmaceuticals Acquires Zikani Therapeutics Eloxx Pharmaceuticals Acquires Zikani Therapeutics
    Piramal Pharma to Acquire Indian API Manufacturer Hemmo Piramal Pharma to Acquire Indian API Manufacturer Hemmo
    Asymchem Expands Oligonucleotides Mfg. Capacity Asymchem Expands Oligonucleotides Mfg. Capacity
    Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise
    BioCentriq, Kytopen Enter Cell Therapy Alliance BioCentriq, Kytopen Enter Cell Therapy Alliance
    Piramal Pharma Solutions, Plus Therapeutics Ink MSA 
 Piramal Pharma Solutions, Plus Therapeutics Ink MSA 

    BioCentriq and Kytopen Enter Cell Therapy Partnership BioCentriq and Kytopen Enter Cell Therapy Partnership
    Plus Therapeutics, Piramal Ink Master Services Agreement Plus Therapeutics, Piramal Ink Master Services Agreement
    Cybin to Leverage Catalent’s Zydis for Psychiatric Drug  Cybin to Leverage Catalent’s Zydis for Psychiatric Drug

    Related Breaking News

    • Bio News | Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | Information Technology
      Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals

      Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals

      Supporting R&D optimization of next-generation biopharmaceuticals with digital technology and drug discovery platform.
      Tim Wright, Editor, Contract Pharma 04.07.21

    • Breaking News | R&D
      JSR Life Sciences Unveils Corporate Venture Fund

      JSR Life Sciences Unveils Corporate Venture Fund

      Aims to foster investment in new companies and innovative technologies.
      Charles Sternberg, Assistant Editor 03.24.21

    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
      Evotec, Takeda Enter Multi-RNA Target Alliance

      Evotec, Takeda Enter Multi-RNA Target Alliance

      To discover and develop small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
      Kristin Brooks 03.22.21


    • Bio News | Breaking News | Collaborations & Alliances | CRO News | Drug Development | Drug Discovery | Industry News | R&D
      Innoforce and dMed Enter Development Collaboration

      Innoforce and dMed Enter Development Collaboration

      Aims to accelerate the development of innovative therapeutics.
      Tim Wright, Editor, Contract Pharma 03.03.21

    • Breaking News | CRO News | Drug Discovery | Industry News | R&D
      Icon to Acquire PRA Health Sciences

      Icon to Acquire PRA Health Sciences

      Brings together two organizations to create a leading healthcare intelligence and clinical CRO.
      Charles Sternberg, Assistant Editor 03.01.21

    • Analytical Services | Breaking News | Drug Discovery | Facilities | Industry News | R&D
      CatSci Opens New Site in UK

      CatSci Opens New Site in UK

      Strengthens analytical capabilities with the opening of a secondary site in Dagenham backed by a $4.2 million investment.
      Tim Wright, Editor, Contract Pharma 02.25.21


    • Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | Information Technology
      CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

      CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

      Will leverage quantum machine learning for novel cancer treatment biomarker discovery.
      Tim Wright, Editor, Contract Pharma 02.25.21

    • Analytical Services | Bioanalytical Services | Breaking News | Chemistry | Facilities | Industry News | Laboratory Testing | R&D
      Almac Group Completes $7M R&D Center

      Almac Group Completes $7M R&D Center

      Significant expansion of biocatalysis, flow chemistry, and peptide capacity.
      Tim Wright, Editor, Contract Pharma 02.23.21

    • Breaking News | R&D
      Wavelength Pharmaceuticals Acquires Majority Stake in Vanamali Organics

      Wavelength Pharmaceuticals Acquires Majority Stake in Vanamali Organics

      Further strengthens its drug substance manufacturing footprint and global supply chain.
      Charles Sternberg, Assistant Editor 02.18.21


    • Breaking News | Collaborations & Alliances | CRO News | Drug Discovery | Industry News | R&D
      Jubilant Biosys, Yale Form Research Alliance

      Jubilant Biosys, Yale Form Research Alliance

      Aims to accelerate small molecule discovery programs leveraging Jubilant's medicinal chemistry, structural biology, in-vitro and in-vivo pharmacology.
      02.10.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Drug Discovery | Industry News | Information Technology
      Evozyne, Takeda Ink Strategic Protein Design Agreement

      Evozyne, Takeda Ink Strategic Protein Design Agreement

      Takeda will use Evozyne's evolution-based protein design technology to research and develop proteins for next-gen gene therapies.
      Kristin Brooks 01.28.21

    • Breaking News | Drug Discovery | Industry News | Preclinical Outsourcing
      X-Chem Acquires IntelliSyn and AviSyn

      X-Chem Acquires IntelliSyn and AviSyn

      Acquisitions allow the company to offer services for screening, hit validation and lead optimization on existing and new markets.
      Kristin Brooks 01.26.21


    • Breaking News | Drug Development | Drug Discovery | Industry News
      Lilly Completes $1B Acquisition of Prevail

      Lilly Completes $1B Acquisition of Prevail

      Adds new modality for drug discovery and development and creates a gene therapy program with neuroscience assets.
      Kristin Brooks 01.22.21

    • Breaking News | Collaborations & Alliances | Drug Discovery
      Metrion, LifeArc Extend Neuroscience Alliance

      Metrion, LifeArc Extend Neuroscience Alliance

      Collaboration extended for another 12 months after successfully progressing into late stage hit-to-lead optimization phase.
      Contract Pharma Staff 01.18.21

    • Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
      Janssen, TenNor Enter NTM Research Pact

      Janssen, TenNor Enter NTM Research Pact

      To leverage TenNor’s multitargeting drug conjugation platform to discover new therapies to treat nontuberculous mycobacteria diseases.
      Contract Pharma Staff 01.18.21

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands 'Beautiful' Fagrance Collection
    Mushrooms Are Key Ingredients in Beauty & Wellness
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login